bs-14542R **[Primary Antibody]**

eIF3B Rabbit pAb

www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

DATASHEET

Host: Rabbit **Isotype:** IgG

Clonality: Polyclonal

GeneID: 8662 **SWISS:** P55884

Target: eIF3B

Immunogen: KLH conjugated synthetic peptide derived from human eIF3B: 701-814/814.

Purification: affinity purified by Protein A

Concentration: 1mg/ml

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: eIF3b expression relates to human bladder and prostate cancer prognosis, is required for tumor growth, and thus a candidate therapeutic target.The initiation of protein synthesis in eukaryotic cells is regulated by interactions between protein initiation factors and RNA molecules. Association of eIF3 proteins with the 40S ribosomal subunit stabilizes eIF2-GTP-Met-tRNAiMet complex association and mRNA binding, and promotes dissociation of 80S ribosomes into 40S and 60S subunits, thereby promoting the assembly of the pre-initiation complex. Overexpression of eIF3 proteins is common in several cancers, suggesting a role for eIF3 proteins in tumorigenesis.

Applications: **IHC-P** (1:100-500)
IHC-F (1:100-500)
IF (1:100-500)
ICC/IF (1:100-500)
ELISA (1:5000-10000)

Reactivity: (predicted: Human, Mouse, Rat, Rabbit, Sheep, Cow, Chicken, Dog, Horse)

Predicted MW.: 92 kDa

Subcellular Location: Cytoplasm

SELECTED CITATIONS

- **[IF=27.7]** Luo Hao. et al. The miR-23a/27a/24 — 2 cluster drives immune evasion and resistance to PD-1/PD-L1 blockade in non-small cell lung cancer. MOL CANCER. 2024 Dec;23(1):1-15 IHC ;Mouse,Human. 39736629